Skip to main content

Grant Funding Opportunities: 12/19/2014

Weekly Grant Funding Opportunities

Please feel free to send special funding search requests any time (susan_craft@ncbiotech.org).  Grant funding requests are included our regular research and include a fee of $100/hour. Also, let us know if any of your partners have submitted grant applications to funding announcements posted in the weekly grant alert emails.  We would love to hear of their successes!

Visit NCBiotech’s Funding Gateway page to get more information on funding announcements, links to opportunity search databases and grant development tips.

 

Announcements

The Defense Advanced Research Projects Agency (DARPA) has simplified its Broad Agency Announcement (BAA) proposal process to better attract and fund new ideas in biotechnology.

This new Biotechnology EZ BAA, overseen by DARPA’s Biological Technologies Office (BTO), provides the opportunity for innovators to receive seed funding of up to $700,000 simply by submitting an initial two-page white paper describing their ideas.

Unlike traditional BAAs, which specify topics and minimum performance requirements, the EZ BAA is open to any idea with the potential to yield revolutionary new capabilities in the biotech. This eliminates the need for proposers to search or wait for specific opportunities relevant to their expertise.

BAAs also typically run 40 to 60 pages and requires highly structured responses from proposers. Under the simplified EZ BAA, DARPA managers will review the 2-page white papers within just a few weeks of submission, and either encourage or discourage submission of a full proposal of no more than 20 pages.


Upcoming Deadlines

Deadline: 1/20/2015

Agency: National Institutes of Health

Program: Stem Cell-Derived Blood Products for Therapeutic Use (R01)

Description: Stem cell technology holds the promise of providing a nearly limitless source of safe, immune-matched cells for clinical use. One of the first areas where this promise can be realized is through cell products that lack a nucleus and thus face fewer regulatory hurdles, such as red blood cells and platelets. Considerable progress has been made but scientific questions remain and improved tools to enhance the production are required if translation to clinical use is to be achieved. To this end, this FOA will support research addressing remaining scientific questions to enable and accelerate the use of stem cell-derived blood products as therapeutics. While production of sufficient numbers of cells such as platelets and red cells has been demonstrated using cellular engineering methods, basic research questions related to cell differentiation and maturation remain, which if elucidated, may allow for the development of new ways to efficiently produce clinically-useful stem cell-derived platelets or red blood cells. In addition to this FOA, two companion FOAs (RFA-HL-15-029 and RFA-HL-15-030) will support small business research to develop improved techniques and tools to enhance the production of clinically-relevant, functional stem cell-derived red blood cells or platelets in a more efficient and cost-effective manner.

Award Amount: $300,000

Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-15-022.html

Eligibility: State, county or city governments; public and private institutes of higher education; school districts; small businesses; nonprofits; Native American tribal organizations; others


Deadline: 1/23/2015

Agency: National Institutes of Health

Program: Non-Traditional Therapeutics that Limit Antibacterial Resistance (R21/R33)

Description: The purpose of this Funding Opportunity Announcement is to solicit applications for early-stage translational research projects focused on discovery and development of novel non-traditional therapeutics that provide alternative treatment modalities for infected patients and address the growing health care threat of increasing antibiotic resistance.

Award Amount: Varies

Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-066.html

Eligibility: State, county or city governments; public and private institutes of higher education; school districts; small businesses; nonprofits; Native American tribal organizations; others


New Opportunities

Deadline: 1/29/2015

Agency: National Institutes of Health

Program: Immune and Inflammatory Mechanisms in Alzheimer's Disease (R01)

Description: The goal of this FOA is to establish the role of the brain innate immune system, the systemic immune system, and the crosstalk and changes with age between the two in the development and progression of Alzheimers disease. An interdisciplinary and integrative research approach to identify the cell networks and meditators of the brain and systemic immune and inflammatory systems is expected to give greater insight into the etiological mechanisms underlying Alzheimers disease.

Award Amount: $500,000

Website: www.grants.gov/web/grants/view-opportunity.html?oppId=260711

Eligibility: State, county or city governments; public and private institutes of higher education; school districts; small businesses; nonprofits; Native American tribal organizations; others


Deadline: 1/24/2015

Agency: National Institutes of Health

Program: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Etiology, Diagnosis, Pathophysiology, and Treatment (R01) 

Description: This Funding Opportunity Announcement (FOA) issued by the Office of Research on Women's Health (ORWH) and co-sponsoring Institutes and Centers (ICs) of the National Institutes of Health (NIH) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology, and treatment of chronic fatigue syndrome (CFS), sometimes referred to as myalgic encephalomyelitis (ME), in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among patient populations, the common mechanisms influencing the multiple body systems that are affected in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of the disease process and provide evidence based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS. This interdisciplinary research may include the building of scientific teams to study and develop biomarkers, innovative treatment modalities, and/or the modifiable risk and protective processes specifically targeted by preventive and/or treatment interventions.

Award Amount: Varies

Website: http://grants.nih.gov/grants/guide/pa-files/PAR-12-032.html

Eligibility: State, county or city governments; public and private institutes of higher education; school districts; small businesses; nonprofits; Native American tribal organizations; others


Deadline: 2/11/2015

Agency: North Carolina Biotechnology Center

Program: Collaborative Funding Grant

Description: The Collaborative Funding Grant (CFG) supports a university-company partnership that will advance a company’s technology toward the marketplace. This grant provides funds for a post-doctoral fellow or technician in a university lab to conduct research on a project of commercial interest. University investigators and companies first form the collaboration and then apply together through the university.

Award Amount: $100,000

Website: www.ncbiotech.org/research-grants/research-funding/collaborative-funding

Eligibility: Principal Investigators are eligible if: They hold a full-time tenure track faculty position at a North Carolina academic institution or a full-time permanent appointment at a non-profit research institution.  See guidelines for details on PIs who hold a position in the partnering company. Companies are eligible if: The company is a North Carolina-based company engaged in life science research, development or manufacturing with demonstrated IP owned or licensed by the company; and additional requirements as indicated in the 2015 Cycle 2 guidelines. OR The company is a national or multinational company with significant presence in North Carolina such as a research or manufacturing facility or regional headquarters. The collaboration must involve the North Carolina entity.


Deadline: 3/7/2015

Agency: National Institutes of Health

Program: Centers for Common Disease Genomics (UM1)

Description: The National Human Genome Research Institute (NHGRI) seeks to fund a collaborative large-scale genome sequencing effort to comprehensively identify rare risk and protective variants contributing to multiple common disease phenotypes. This initiative will explore a range of diseases with the ultimate goal of undertaking variant discovery for enough different examples of disease architectures and study designs to better understand the general principles of genomic architecture underlying common, complex inherited diseases; understand how best to design rare variant studies for common disease; and develop resources, informatics tools, and innovative approaches and technologies for multiple disease research communities and the wider biomedical research community.

Award Amount: $ 40,000,000

Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-15-001.html

Eligibility: State, county or city governments; public and private institutes of higher education; school districts; small businesses; nonprofits; Native American tribal organizations; others

Add new comment

Refresh Type the characters you see in this picture.
Type the characters you see in the picture; if you can't read them, submit the form and a new image will be generated. Not case sensitive.  Switch to audio verification.